Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Product/Service, Webcast

Certara Announces the Availability of PK Submit, its Pharmacokinetic CDISC Technology Solution

Certara®, the global model-informed drug development and decision support leader, today announced the availability of PK Submittm, a technology solution for automating the creation of PK Clinical Data Interchange Standards Consortium (CDISC) domains during Non-Compartmental Analysis (NCA). The US Food and Drug Administration (FDA) and Japan's Pharmaceuticals and Medical Devices Agency (PMDA) both require that CDISC study data standards be applied to preclinical and clinical data submitted electronically as part of a new drug application (NDA).

"As the number of clinical trials being conducted has grown tremendously, it is spurring an equally dramatic increase in the number of new drug and biologics license applications being filed," said Michael Eckstut, senior vice president and head of Certara's pharmacometrics software group. "It is now more important than ever that sponsors have access to tools that can automate standardized, manual processes, such as the creation of CDISC files, thus increasing accuracy, improving data organization, and ensuring compliance. Our clients are also finding significant time reductions, thus shortening the time to file regulatory submissions."

CDISC guidelines apply to all new drug applications (NDAs), investigational new drug applications (INDs), abbreviated new drug applications (ANDAs), and certain biologics license applications. In fact, PK CDISC domains are required when developing the preclinical Standard for Exchange of Nonclinical Data (SEND) and clinical Study Data Tabulation Model (SDTM) datasets needed for a regulatory submission package.

"Customer feedback from our recent Phoenix User Group Meeting further validated the benefits of using our PK Submit tool to make PK workflows more efficient. Customers reported that without PK Submit, it could take anywhere from weeks to months to navigate internal resources to create these domains. As this is one of the final steps in preparing a regulatory package for submission, any delays directly increase time to submission and therefore incur cost," said Kevin Trimm, head of product management for Certara's pharmacometrics software portfolio.

PK Submit is integrated with Certara's Phoenix WinNonlintm software and supports the automatic generation of a complete electronic PK regulatory submission package, including all necessary CDISC domains, a validation report, study data reviewers guide, and define file during the normal process of setting up and executing an NCA. These documents can all be generated within minutes, from the same source, by a PK scientist who does not need to be a CDISC expert.

Mr. Trimm will discuss the benefits of using PK Submit further during the 2020 CDISC EMEA TechniCon conference at 8:25 a.m. ET / 2:25 p.m. CET on Jan. 27. This inaugural virtual conference will showcase new technologies, including the CDISC Library API, offered by CDISC member organizations and open-source development companies. Additional information about this conference can be found at www.cdisc.org/2020-cdisc-technicon.

Interested parties can also learn more about PK Submit by viewing the webinar at https://www.certara.com/webinar-archive/create-pk-cdisc-domains-in-minutes-using-pk-submit%ef%b8%8f/?UTM_LeadSource=07312019.

Certara is a CDISC Registered Solutions Provider and has a seat on the CDISC Advisory Council.

About Certara

Certara optimizes R&D productivity, commercial value and patient outcomes through its unique portfolio of model-informed drug development, regulatory science, and market access solutions. In fact, 90+% of all novel drugs approved by the US FDA in the past four years were supported by Certara software or services. Its clients include 1,600 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 60 countries. For more information, visit www.certara.com.

These press releases may also interest you

at 19:05
FOR EU TRADE AND MEDICAL MEDIA ONLY. NOT FOR DISTRIBUTION IN BENELUX. The Janssen Pharmaceutical Companies of Johnson & Johnson announced yesterday interim results from the CHRYSALIS study (NCT02609776) evaluating amivantamab, a fully human...

at 18:56
Changhong(Shanghai: 600839), one of the leading home appliance manufacturers in China, signed an agreement with China National Badminton Team at a signing ceremony held in Chengdu, Sichuan Province, on September 16, to become the official sponsor of...

at 18:03
On September 20, 2020, Guangzhou-based company Guoyao Tech announced a roadmap to complete a prototype launch of 10 kg by 2022 and short-range tonnage launch by electromagnetic by 2023. The company is developing a novel launch system - based on...

at 15:00
Positron, a leading provider of XR Cinema systems, known for its acclaimed Voyager® VR motion chair, announced today the launch of a global intellectual licensing program. The Positron IP Licensing program will make available the patents, designs and...

at 15:00
Last week, at Demand Gen Summit 2020, conversation marketing optimization company ChatFunnels announced the winners of the 2020 Demand Gen Awardstm. The award identifies outstanding individuals in the sales and marketing industry that have driven...

at 14:01
Eli Lilly and Company today announced Verzenio® (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) significantly decreased the risk of breast cancer recurrence by 25 percent compared to standard adjuvant ET alone for people...

News published on 21 november 2019 at 08:05 and distributed by: